{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:05:14Z","timestamp":1789380314022,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"DOI":"10.1007\/s40259-026-00806-9","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:27:06Z","timestamp":1789378026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biosimilars: A Virtuous Cycle of Sustainability and Innovation"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3002-6004","authenticated-orcid":false,"given":"Fernando","family":"de Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Merino-Boh\u00f3rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"R\u00edo-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"806_CR1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. CHMP\/437\/04 Rev. 1. 2014."},{"key":"806_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bcp.12656","volume":"80","author":"F de Mora","year":"2015","unstructured":"de Mora F. Biosimilar: what it is not. Br J Clin Pharmacol. 2015;80:949\u201356. https:\/\/doi.org\/10.1111\/bcp.12656.","journal-title":"Br J Clin Pharmacol"},{"key":"806_CR3","unstructured":"World Health Organization. List of National Regulatory Authorities (NRAs) operating at maturity level 3 (ML3) and maturity level 4 (ML4). 2026. https:\/\/www.who.int\/publications\/m\/item\/list-of-nras-operating-at-ml3-and-ml4. Accessed 15 Jul 2026."},{"key":"806_CR4","unstructured":"World Health Organization. List of WHO listed authorities (WLAs). 2025. https:\/\/www.who.int\/publications\/m\/item\/list-of-who-listed-authorities-wlas. Accessed 15 Jul 2026."},{"issue":"6","key":"806_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","volume":"75","author":"T D\u00f6rner","year":"2016","unstructured":"D\u00f6rner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75(6):974\u201382. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209166.","journal-title":"Ann Rheum Dis"},{"key":"806_CR6","unstructured":"Permanent Pharmacy Commission of the Interterritorial Council of the National Health System, Ministry of Health, Consumer Affairs and Social Welfare. Action plan to promote the use of market-regulating medicines in the National Health System: biosimilar medicines and generic medicines. Draft [in Spanish]. 2019."},{"issue":"4","key":"806_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40259-019-00360-7","volume":"33","author":"F de Mora","year":"2019","unstructured":"de Mora F. Biosimilars: a value proposition. BioDrugs. 2019;33(4):353\u20136. https:\/\/doi.org\/10.1007\/s40259-019-00360-7.","journal-title":"BioDrugs"},{"key":"806_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198\u2013206. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202603.","journal-title":"Ann Rheum Dis"},{"key":"806_CR9","unstructured":"IMS. Delivering on the potential of biosimilar medicines. 2016. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/03\/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf. Accessed 15 Jul 2026."},{"issue":"34","key":"806_CR10","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3748\/wjg.v23.i34.6294","volume":"23","author":"M P\u00e9ntek","year":"2017","unstructured":"P\u00e9ntek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn\u2019s disease in ten European countries. World J Gastroenterol. 2017;23(34):6294\u2013305. https:\/\/doi.org\/10.3748\/wjg.v23.i34.6294.","journal-title":"World J Gastroenterol"},{"key":"806_CR11","unstructured":"Simon-Kucher & Partners. Payers' price and market access policies supporting a sustainable biosimilar medicines market. Final report. 2016. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/09\/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication2.pdf. Accessed 15 Jul 2026."},{"key":"806_CR12","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Xolair. EMA\/404869\/2020. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/xolair-h-c-606-ii-0101-epar-assessment-report-variation_en.pdf. Accessed 15 Jul 2026."},{"key":"806_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ebiom.2018.06.022","volume":"33","author":"J Nanchahal","year":"2018","unstructured":"Nanchahal J, Ball C, Davidson D, et al. Anti-tumour necrosis factor therapy for Dupuytren\u2019s disease: a randomised dose-response proof-of-concept phase 2a clinical trial. EBioMedicine. 2018;33:282\u20138. https:\/\/doi.org\/10.1016\/j.ebiom.2018.06.022.","journal-title":"EBioMedicine"},{"issue":"Suppl 1","key":"806_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-139157","volume":"136","author":"C Luo","year":"2020","unstructured":"Luo C, Wu G, Huang X, et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Blood. 2020;136(Suppl 1):40\u20131.","journal-title":"Blood"},{"key":"806_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82841-w","volume":"11","author":"C Luo","year":"2021","unstructured":"Luo C, Wu G, Huang X, et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep. 2021;11:3255. https:\/\/doi.org\/10.1038\/s41598-021-82841-w.","journal-title":"Sci Rep"},{"issue":"8","key":"806_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30501-6","volume":"18","author":"P Venkatesan","year":"2017","unstructured":"Venkatesan P. NICE recommends routine NHS funding for Kadcyla. Lancet Oncol. 2017;18(8):e435. https:\/\/doi.org\/10.1016\/S1470-2045(17)30501-6.","journal-title":"Lancet Oncol"},{"key":"806_CR17","unstructured":"IQVIA. Perspectives on the availability of innovative medicines. White paper. 2021. https:\/\/www.iqvia.com\/library\/white-papers\/perspectives-on-the-availability-of-innovative-medicines. Accessed 15 Jul 2026."},{"key":"806_CR18","unstructured":"IQVIA. Understanding net pharmaceutical expenditure dynamics in Europe. White paper. 2022. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/iqvia-understanding-net-pharmaceutical-expenditure-dynamics-in-europe.pdf. Accessed 15 Jul 2026."},{"key":"806_CR19","unstructured":"British Generic Manufacturers Association. Sustainability: generics and the NHS. 2012. https:\/\/www.medicinesuk.com\/static\/assets\/1337768331_BGMASustainabilityActionPlan2012.pdf. Accessed 15 Jul 2026."},{"key":"806_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40744-016-0041-3","volume":"3","author":"P Nash","year":"2016","unstructured":"Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg\/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3:257\u201370. https:\/\/doi.org\/10.1007\/s40744-016-0041-3.","journal-title":"Rheumatol Ther"},{"key":"806_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4172\/jbb.1000075","volume":"3","author":"GJ Rivi\u00e8re","year":"2011","unstructured":"Rivi\u00e8re GJ, Yeh CM, Reynolds CV, et al. Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation. J Bioequiv Availab. 2011;3:144\u201350. https:\/\/doi.org\/10.4172\/jbb.1000075.","journal-title":"J Bioequiv Availab"},{"key":"806_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40261-013-0127-4","volume":"33","author":"A Chioato","year":"2013","unstructured":"Chioato A, Noseda E, Colin L, et al. Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study in healthy subjects. Clin Drug Investig. 2013;33:801\u20138. https:\/\/doi.org\/10.1007\/s40261-013-0127-4.","journal-title":"Clin Drug Investig"},{"key":"806_CR23","first-page":"1","volume":"113","author":"L McGahan","year":"2008","unstructured":"McGahan L. Continuous erythropoietin receptor activator (Mircera\u00ae) for renal anemia. Issues Emerg Health Technol. 2008;113:1\u20136.","journal-title":"Issues Emerg Health Technol"},{"key":"806_CR24","unstructured":"European Medicines Agency. Herceptin-H-C-278-X-0060: EPAR-assessment report-extension. EMA\/CHMP\/751770\/2012 Corr. 1. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/herceptin-h-c-278-x-0060-epar-assessment-report-extension_en.pdf. Accessed 15 Jul 2026."},{"key":"806_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s10198-023-01648-w","volume":"25","author":"G Kirshner","year":"2024","unstructured":"Kirshner G, Makai P, Brouns C, et al. The impact of an \u201cevergreening\u201d strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands. Eur J Health Econ. 2024;25:1147\u201363. https:\/\/doi.org\/10.1007\/s10198-023-01648-w.","journal-title":"Eur J Health Econ"},{"key":"806_CR26","unstructured":"European Medicines Agency. MabThera-H-C-165-X-83: EPAR-assessment report-extension. EMA\/CHMP\/71722\/2014. 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera. Accessed 15 Jul 2026."},{"issue":"10432","key":"806_CR27","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1.","journal-title":"Lancet"},{"issue":"3","key":"806_CR28","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):562\u201372. https:\/\/doi.org\/10.1053\/j.gastro.2019.08.027.","journal-title":"Gastroenterology"},{"issue":"1","key":"806_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","volume":"16","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, D\u2019Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16(1):27\u201338. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab133.","journal-title":"J Crohns Colitis"},{"issue":"14","key":"806_CR30","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1177\/13524585211003020","volume":"27","author":"M Trojano","year":"2021","unstructured":"Trojano M, Rami\u00f2-Torrent\u00e0 L, Grimaldi LM, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler. 2021;27(14):2240\u201353. https:\/\/doi.org\/10.1177\/13524585211003020.","journal-title":"Mult Scler"},{"key":"806_CR31","unstructured":"US Food and Drug Administration. Herceptin Hylecta prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761106Orig1s000lbl.pdf. Accessed 15 Jul 2026."},{"issue":"Suppl 1","key":"806_CR32","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1093\/ecco-jcc\/jjz203.023","volume":"14","author":"S Ben-Horin","year":"2020","unstructured":"Ben-Horin S, Leszczyszyn J, Dudkowiak R, et al. OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 2020;14(Suppl 1):S21\u20132. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz203.023.","journal-title":"J Crohns Colitis"},{"key":"806_CR33","unstructured":"European Medicines Agency. Assessment report on extension(s) of marketing authorisation: Remsima. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/remsima-h-c-2576-x-0062-epar-assessment-report-variation_en.pdf. Accessed 15 Jul 2026."},{"key":"806_CR34","unstructured":"European Medicines Agency. Assessment report: Ipique. EMA\/CHMP\/180855\/2022. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ipique-epar-refusal-public-assessment-report_en.pdf. Accessed 15 Jul 2026."},{"key":"806_CR35","unstructured":"European Medicines Agency. Lytenava (bevacizumab gamma): CHMP assessment report. Procedure No. EMEA\/H\/C\/005723\/0000. EMA\/146883\/2024. 21 Mar 2024. [URL]. Accessed 15 Jul 2026."},{"key":"806_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ph14040348","volume":"14","author":"M Garc\u00eda-Go\u00f1i","year":"2009","unstructured":"Garc\u00eda-Go\u00f1i M, R\u00edo-\u00c1lvarez I, Carcedo D, et al. Budget impact analysis of biosimilar products in Spain in the period 2009-2019. Pharmaceuticals (Basel). 2009;14:348. https:\/\/doi.org\/10.3390\/ph14040348.","journal-title":"Pharmaceuticals (Basel)"},{"key":"806_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152023","volume":"55","author":"S Schreiber","year":"2022","unstructured":"Schreiber S, Puig L, Gon\u00e7alves J, et al. Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases. Semin Arthritis Rheum. 2022;55:152023. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152023.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"806_CR38","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1515\/cclm-2015-0987","volume":"54","author":"EMH Schmitz","year":"2016","unstructured":"Schmitz EMH, van de Kerkhof D, Hamann D, et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med. 2016;54(7):1211\u20139. https:\/\/doi.org\/10.1515\/cclm-2015-0987.","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"806_CR39","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2015-208684","volume":"75","author":"MB Ruiz-Arg\u00fcello","year":"2016","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Ruiz del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75(9):1693\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208684.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"806_CR40","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s10067-017-3686-6","volume":"36","author":"EMH Schmitz","year":"2017","unstructured":"Schmitz EMH, Benoy-De Keuster S, Meier AJL, et al. Therapeutic drug monitoring as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clin Rheumatol. 2017;36(9):2129\u201334. https:\/\/doi.org\/10.1007\/s10067-017-3686-6.","journal-title":"Clin Rheumatol"},{"key":"806_CR41","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. EMA\/CHMP\/BMWP\/403543\/2010. 2014."},{"key":"806_CR42","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Bemfola. EMA\/65507\/2013. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/bemfola-epar-public-assessment-report_en.pdf. Accessed 15 Jul 2026."},{"issue":"3","key":"806_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ejhpharm-2016-001085","volume":"25","author":"J Kim","year":"2018","unstructured":"Kim J, Chung J, Park S, et al. Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab). Eur J Hosp Pharm. 2018;25(3):157\u201364. https:\/\/doi.org\/10.1136\/ejhpharm-2016-001085.","journal-title":"Eur J Hosp Pharm"},{"issue":"6","key":"806_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40259-018-0314-1","volume":"32","author":"S Kim","year":"2018","unstructured":"Kim S, Lee JW, Kang HY, et al. In-use physicochemical and biological stability of the trastuzumab biosimilar CT-P6 upon preparation for intravenous infusion. BioDrugs. 2018;32(6):619\u201325. https:\/\/doi.org\/10.1007\/s40259-018-0314-1.","journal-title":"BioDrugs"},{"key":"806_CR45","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1007\/s12325-020-01465-0","volume":"37","author":"D Park","year":"2020","unstructured":"Park D, Kim K, Yun J, et al. Evaluation of the physico-chemical and biological stability of SB8 (Aybintio), a proposed biosimilar to bevacizumab, under ambient and in-use conditions. Adv Ther. 2020;37:4308\u201324. https:\/\/doi.org\/10.1007\/s12325-020-01465-0.","journal-title":"Adv Ther"},{"key":"806_CR46","unstructured":"European Medicines Agency. Aybintio: EPAR-public assessment report. EMA\/380645\/2020. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/aybintio-epar-public-assessment-report_en.pdf. Accessed 15 Jul 2026."},{"key":"806_CR47","unstructured":"European Medicines Agency. Alymsys: EPAR-public assessment report. EMA\/112177\/2021. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alymsys. Accessed 15 Jul 2026."},{"issue":"4","key":"806_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5639\/gabij.2020.0904.026","volume":"9","author":"J Seckute","year":"2020","unstructured":"Seckute J, Castellanos I, Bane S. Physicochemical stability of the bevacizumab biosimilar ABP 215 after preparation and storage in intravenous bags. GaBI J. 2020;9(4):155\u201362. https:\/\/doi.org\/10.5639\/gabij.2020.0904.026.","journal-title":"GaBI J."},{"issue":"4","key":"806_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1080\/19420862.2017.1305530","volume":"9","author":"S Kim","year":"2017","unstructured":"Kim S, Song J, Park S, et al. Drifts in ADCC-related quality attributes of Herceptin\u00ae: impact on development of a trastuzumab biosimilar. MAbs. 2017;9(4):704\u201314. https:\/\/doi.org\/10.1080\/19420862.2017.1305530.","journal-title":"MAbs"},{"key":"806_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04320-5","volume":"7","author":"WC Lamanna","year":"2017","unstructured":"Lamanna WC, Mayer RE, Rupprechter A, et al. The structure-function relationship of disulfide bonds in etanercept. Sci Rep. 2017;7:3951. https:\/\/doi.org\/10.1038\/s41598-017-04320-5.","journal-title":"Sci Rep"},{"issue":"4","key":"806_CR51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/19420862.2018.1440170","volume":"10","author":"J Lee","year":"2018","unstructured":"Lee J, Kang HA, Bae JS, et al. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. MAbs. 2018;10(4):547\u201371. https:\/\/doi.org\/10.1080\/19420862.2018.1440170.","journal-title":"MAbs"},{"key":"806_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.832059","volume":"10","author":"N Nupur","year":"2022","unstructured":"Nupur N, Joshi S, Guillarme D, et al. Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Front Bioeng Biotechnol. 2022;10:832059. https:\/\/doi.org\/10.3389\/fbioe.2022.832059.","journal-title":"Front Bioeng Biotechnol."},{"key":"806_CR53","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40259-014-0088-z","volume":"28","author":"S Ramanan","year":"2014","unstructured":"Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28:363\u201372. https:\/\/doi.org\/10.1007\/s40259-014-0088-z.","journal-title":"BioDrugs"},{"key":"806_CR54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nbt.1839","volume":"29","author":"M Schiestl","year":"2011","unstructured":"Schiestl M, Stangler T, Torella C. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310\u20132. https:\/\/doi.org\/10.1038\/nbt.1839.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"806_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/14712598.2018.1421169","volume":"18","author":"WC Lamanna","year":"2018","unstructured":"Lamanna WC, Holzmann J, Cohen HP, et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther. 2018;18(4):369\u201379. https:\/\/doi.org\/10.1080\/14712598.2018.1421169.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"806_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2012-202941","volume":"72","author":"CK Schneider","year":"2013","unstructured":"Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202941.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"806_CR57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40259-019-00362-5","volume":"33","author":"JH Lee","year":"2019","unstructured":"Lee JH, Paek K, Moon JH, et al. Biological characterization of SB3, a trastuzumab biosimilar, and the influence of changes in reference product characteristics on the similarity assessment. BioDrugs. 2019;33(4):411\u201322. https:\/\/doi.org\/10.1007\/s40259-019-00362-5.","journal-title":"BioDrugs"},{"key":"806_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.015","volume":"120","author":"X Pivot","year":"2019","unstructured":"Pivot X, Pegram M, Cortes J, et al. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019;120:1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.015.","journal-title":"Eur J Cancer"},{"key":"806_CR59","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s12325-019-01027-z","volume":"36","author":"YH Rho","year":"2019","unstructured":"Rho YH, Rychlewska-Ha\u0144czewska A, \u015aliwowska B, et al. Usability of prefilled syringe and autoinjector for SB4 (an etanercept biosimilar) in patients with rheumatoid arthritis. Adv Ther. 2019;36:2287\u201395. https:\/\/doi.org\/10.1007\/s12325-019-01027-z.","journal-title":"Adv Ther"},{"key":"806_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-016-0164-y","volume":"14","author":"T Strowitzki","year":"2016","unstructured":"Strowitzki T, Kuczynski W, Mueller A, et al. Safety and efficacy of Ovaleap\u00ae (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to main study. Reprod Biol Endocrinol. 2016;14:31. https:\/\/doi.org\/10.1186\/s12958-016-0164-y.","journal-title":"Reprod Biol Endocrinol"},{"issue":"12","key":"806_CR61","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1517\/17425247.2014.965676","volume":"11","author":"B Imthurn","year":"2014","unstructured":"Imthurn B, McVeigh E, Stiller R, et al. Evaluation of the use and handling of three different pen systems considered for in vitro fertilization treatment. Expert Opin Drug Deliv. 2014;11(12):1859\u201364. https:\/\/doi.org\/10.1517\/17425247.2014.965676.","journal-title":"Expert Opin Drug Deliv"},{"key":"806_CR62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40744-016-0035-1","volume":"3","author":"K Thakur","year":"2016","unstructured":"Thakur K, Biberger A, Handrich A, et al. Perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: a new European Union-approved etanercept biosimilar (Benepali\u00ae) versus etanercept (Enbrel\u00ae)-findings from a nurse survey in Europe. Rheumatol Ther. 2016;3:77\u201389. https:\/\/doi.org\/10.1007\/s40744-016-0035-1.","journal-title":"Rheumatol Ther"},{"key":"806_CR63","unstructured":"European Medicines Agency. Omlyclo: EPAR-product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omlyclo-epar-product-information_en.pdf. Accessed 15 Jul 2026."},{"key":"806_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/antib8010021","volume":"8","author":"E Doevendans","year":"2019","unstructured":"Doevendans E, Schellekens H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies (Basel). 2019;8:21. https:\/\/doi.org\/10.3390\/antib8010021.","journal-title":"Antibodies (Basel)"},{"key":"806_CR65","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). EPAR: Erelzi. EMA\/CHMP\/302222\/2017. 2017."},{"issue":"12","key":"806_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0799-0","volume":"20","author":"L Chadwick","year":"2018","unstructured":"Chadwick L, Zhao S, Mysler E, et al. Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(12):84. https:\/\/doi.org\/10.1007\/s11926-018-0799-0.","journal-title":"Curr Rheumatol Rep"},{"key":"806_CR67","unstructured":"IQVIA. The impact of biosimilar competition in Europe. 2020. https:\/\/www.iqvia.com\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe. Accessed 15 Jul 2026."},{"issue":"e1","key":"806_CR68","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1136\/ejhpharm-2021-002955","volume":"30","author":"MA Calleja","year":"2023","unstructured":"Calleja MA, Albanell J, Aranda E, et al. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. Eur J Hosp Pharm. 2023;30(e1):e40\u20137. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002955.","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"806_CR69","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2021.3.2377","volume":"19","author":"D Choquette","year":"2021","unstructured":"Choquette D, Chan J, Bardi M, et al. Monitoring the transition of patients on biologics in rheumatoid arthritis: consensus guidance for pharmacists. Pharm Pract (Granada). 2021;19(3):2377. https:\/\/doi.org\/10.18549\/PharmPract.2021.3.2377.","journal-title":"Pharm Pract (Granada)"},{"key":"806_CR70","unstructured":"World Health Organization. Defined daily dose (DDD). https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 15 Jul 2026."},{"issue":"6","key":"806_CR71","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2019;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"key":"806_CR72","unstructured":"National Institute for Health and Care Excellence. A partial review of TA375 for patients with moderate disease only will be planned into the appraisal work programme. 2019. https:\/\/www.nice.org.uk\/guidance\/ta375\/evidence\/review-proposal-paper-pdf-6904907822. Accessed 15 Jul 2026."},{"key":"806_CR73","unstructured":"National Institute for Health and Care Excellence. Decision to conduct a partial review of TA375 for patients with moderate disease only. 2019. https:\/\/www.nice.org.uk\/guidance\/ta375\/resources\/review-decision--september-2019-pdf-8948760536005. Accessed 15 Jul 2026."},{"key":"806_CR74","unstructured":"National Institute for Health and Care Excellence. Final appraisal document: adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375). 2021. https:\/\/www.nice.org.uk\/guidance\/ta715\/documents\/final-appraisal-determination-document. Accessed 15 Jul 2026."},{"key":"806_CR75","unstructured":"National Institute for Health and Care Excellence. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. 2019. https:\/\/www.nice.org.uk\/guidance\/ta569. Accessed 15 Jul 2026."},{"issue":"1","key":"806_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010048","volume":"13","author":"J Tornero Molina","year":"2024","unstructured":"Tornero Molina J, Hern\u00e1ndez-Cruz B, Corominas H. Initial treatment with biological therapy in rheumatoid arthritis. J Clin Med. 2024;13(1):48. https:\/\/doi.org\/10.3390\/jcm13010048.","journal-title":"J Clin Med"},{"issue":"9","key":"806_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf150","volume":"19","author":"NM Noor","year":"2025","unstructured":"Noor NM, Davies N, Tahir W, et al. Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional \u201cstep-up\u201d care for patients with active Crohn\u2019s disease: a cost-effectiveness analysis from the PROFILE trial. J Crohns Colitis. 2025;19(9):jjaf150. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf150.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"806_CR78","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22(7):977\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00252-7.","journal-title":"Lancet Oncol"},{"issue":"3","key":"806_CR79","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","volume":"20","author":"W Ahmed","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361\u201379. https:\/\/doi.org\/10.1016\/j.cgh.2021.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"806_CR80","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MCG.0000000000001583","volume":"55","author":"M Haider","year":"2021","unstructured":"Haider M, Lashner B. Dual targeted therapy for the management of inflammatory bowel disease. J Clin Gastroenterol. 2021;55:661\u20136. https:\/\/doi.org\/10.1097\/MCG.0000000000001583.","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"806_CR81","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2021-221812","volume":"81","author":"C Valero","year":"2022","unstructured":"Valero C, Baldivieso JP, Gonzalez-Alvaro I, et al. Effectiveness and safety of combined biological therapy in patients with refractory multidomain spondyloarthritis. Ann Rheum Dis. 2022;81(6):899\u2013901. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221812.","journal-title":"Ann Rheum Dis"},{"key":"806_CR82","doi-asserted-by":"publisher","first-page":"1283251","DOI":"10.3389\/fimmu.2023.1283251","volume":"14","author":"C Valero-Mart\u00ednez","year":"2023","unstructured":"Valero-Mart\u00ednez C, Font-Urgelles J, Sall\u00e9s M, et al. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Front Immunol. 2023;14:1283251. https:\/\/doi.org\/10.3389\/fimmu.2023.1283251.","journal-title":"Front Immunol"},{"key":"806_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017.","journal-title":"Cancer Treat Rev"},{"key":"806_CR84","unstructured":"ClinicalTrials.gov. Combination therapy for BRAF-V600E metastatic CRCm (BRAVE). NCT06411600. 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT06411600. Accessed 15 Jul 2026."},{"key":"806_CR85","unstructured":"European Medicines Agency, Heads of Medicines Agencies. HMA-EMA Joint Big Data Taskforce Phase II report: evolving data-driven regulation. EMA\/520966\/2019. 2020. https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/big-data. Accessed 15 Jul 2026."},{"key":"806_CR86","unstructured":"Directorate-General for Internal Policies of the Union. Background note on shared knowledge in cancer care and research. 2021. https:\/\/www.europarl.europa.eu\/cmsdata\/231854\/2021-04-15_FINAL%20Background%20note_Shared%20knowledge.pdf. Accessed 15 Jul 2026."},{"key":"806_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04897-7","volume":"24","author":"BMF Penninx","year":"2026","unstructured":"Penninx BMF, Tas SW, Timmers L, et al. Rational use of expensive medicines in the Netherlands: strategies to improve effectiveness and reduce burden on patients and society-a narrative review. BMC Med. 2026;24:363. https:\/\/doi.org\/10.1186\/s12916-026-04897-7.","journal-title":"BMC Med"},{"key":"806_CR88","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","volume":"33","author":"E Wolff-Holz","year":"2019","unstructured":"Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33:621\u201334. https:\/\/doi.org\/10.1007\/s40259-019-00377-y.","journal-title":"BioDrugs"},{"key":"806_CR89","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40259-022-00533-x","volume":"36","author":"P Kurki","year":"2022","unstructured":"Kurki P, Kang HN, Ekman N, et al. Regulatory evaluation of biosimilars: refinement of principles based on the scientific evidence and clinical experience. BioDrugs. 2022;36:359\u201371. https:\/\/doi.org\/10.1007\/s40259-022-00533-x.","journal-title":"BioDrugs"},{"key":"806_CR90","unstructured":"European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development. EMA\/CHMP\/BMWP\/60916\/2025. Adopted 16 March 2026. https:\/\/www.ema.europa.eu\/en\/documents\/other\/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf. Accessed 15 Jul 2026."},{"issue":"1","key":"806_CR91","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/cpt.1653","volume":"107","author":"J Li","year":"2020","unstructured":"Li J, Florian J, Campbell E, et al. Advancing biosimilar development using pharmacodynamic biomarkers in clinical pharmacology studies. Clin Pharmacol Ther. 2020;107(1):40\u20132. https:\/\/doi.org\/10.1002\/cpt.1653.","journal-title":"Clin Pharmacol Ther"},{"key":"806_CR92","unstructured":"Warhem V. Incentivising pharmaceutical off-patent innovation in the EU. cepInput. Centre de Politique Europ\u00e9enne. 2021. https:\/\/www.cep.eu\/fileadmin\/user_upload\/cep.eu\/Studien\/cepInput_Off_Patent_Innovation\/cepInput_Incentivising_Pharmaceutical_Off-Patent_Innovation_in_the_EU.pdf. Accessed 15 Jul 2026."},{"key":"806_CR93","unstructured":"US Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. 2018. https:\/\/www.fda.gov\/media\/114574\/download. Accessed 15 Jul 2026."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00806-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:27:24Z","timestamp":1789378044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00806-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":93,"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00806-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"12 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.R.-\u00c1. is employee of the Spanish Biosimilar Medicines Association. F.d.M., V.M.-B., and R.G.-V.: No conflicts of interest declared.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.d.M. is an Editorial Board member of Biodrugs. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","label":"Editorial Board Member Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.d.M. co-conceived the manuscript, drafted the initial manuscript and conducted the bibliographic research supporting the identification and discussion of biosimilar-driven innovation areas. V.M.-B. reviewed an advanced version of the manuscript and contributed specific examples of pharmacy-related innovation. R.G.-V. reviewed an advanced version of the manuscript and contributed specific examples of biosimilars-driven innovation in rheumatology. I.R.-\u00c1. co-conceived the manuscript and critically revised the draft to produce the final version.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}